Blackhawk Submits SARS-CoV-2 IgG / IgM Rapid Test Kit Vancouver, British Columbia - TheNewswire - November 9, 2020 - Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (the "Corporation" or "Blackhawk"), is pleased to provide the following corporate update.
The Health Canada Interim Order ("IO") application was completed and submitted for its SARS-CoV-2 IgG / IgM Rapid Test Kit.
The extensive application was submitted November 4th and Health Canada confirmed receipt of the application the same day.
Even though Blackhawk cannot guarantee timelines, the anticipated time to process the application is between 40 and 60 days.
The SARS-CoV-2 IgG / IgM Rapid Test Kit currently holds Federal Drug Administration (FDA) Emergency Use Authorization (EUA) as well as a CE Mark in Europe.
https://www.thenewswire.com/press-releases/1LYzFPdZ7-blackhawk-submits-sars-cov-2-igg-igm-rapid-test-kit-interim-order-application-and-provides-update-on-previously-submitted-exprobe-sars-cov-2-testing-kit.html